Please note that the copy function is not enabled for this field.
If you wish to
modify
existing outcomes, please copy and paste the current outcome text into the Update field.
LOGIN
CREATE ACCOUNT
LOGIN
CREATE ACCOUNT
MY TRIALS
REGISTER TRIAL
FAQs
HINTS AND TIPS
DEFINITIONS
Trial Review
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been endorsed by the ANZCTR. Before participating in a study, talk to your health care provider and refer to this
information for consumers
Download to PDF
Trial details imported from ClinicalTrials.gov
For full trial details, please see the original record at
https://clinicaltrials.gov/ct2/show/NCT04853368
Registration number
NCT04853368
Ethics application status
Date submitted
19/04/2021
Date registered
21/04/2021
Date last updated
22/06/2023
Titles & IDs
Public title
Study to Evaluate Adverse Events and Change in Disease Activity With Oral Capsules of Galicaftor/Navocaftor/ABBV-119 or Galicaftor/Navocaftor/ABBV-576 Combination Therapies in Adult Participants With Cystic Fibrosis
Query!
Scientific title
A Phase 2 Study of Galicaftor/Navocaftor/ABBV-119 or Galicaftor/Navocaftor/ABBV-576 Combination Therapies in Subjects With Cystic Fibrosis Who Are Homozygous or Heterozygous for the F508del Mutation
Query!
Secondary ID [1]
0
0
2020-005805-25
Query!
Secondary ID [2]
0
0
M19-771
Query!
Universal Trial Number (UTN)
Query!
Trial acronym
Query!
Linked study record
Query!
Health condition
Health condition(s) or problem(s) studied:
Cystic Fibrosis (CF)
0
0
Query!
Condition category
Condition code
Human Genetics and Inherited Disorders
0
0
0
0
Query!
Cystic fibrosis
Query!
Respiratory
0
0
0
0
Query!
Other respiratory disorders / diseases
Query!
Oral and Gastrointestinal
0
0
0
0
Query!
Other diseases of the mouth, teeth, oesophagus, digestive system including liver and colon
Query!
Inflammatory and Immune System
0
0
0
0
Query!
Connective tissue diseases
Query!
Inflammatory and Immune System
0
0
0
0
Query!
Other inflammatory or immune system disorders
Query!
Intervention/exposure
Study type
Interventional
Query!
Description of intervention(s) / exposure
Treatment: Drugs - ABBV-576
Treatment: Drugs - Galicaftor
Treatment: Drugs - Placebo
Treatment: Drugs - Navocaftor
Treatment: Drugs - ABBV-119
Experimental: F508del Homozygous Cystic Fibrosis (CF) Participants - F508del homozygous cystic fibrosis (CF) participants receive galicaftor/navocaftor dual combination (28 days) followed by galicaftor/navocaftor/ABBV-119 triple combination therapy (28 days).
Experimental: F508del Heterozygous CF Participants (Active Drug Group) - F508del heterozygous CF participants receive galicaftor/navocaftor/ABBV-119 combination therapy (28 days).
Placebo Comparator: F508del Heterozygous CF Participants (Placebo Group) - F508del heterozygous CF participants receive placebo (28 days).
Experimental: F508del Homozygous and Heterozygous CF Participants - F508del homozygous and heterozygous CF participants receive galicaftor/navocaftor/ABBV-576 triple combination therapy for 28 days.
Treatment: Drugs: ABBV-576
Oral capsules
Treatment: Drugs: Galicaftor
Oral capsules
Treatment: Drugs: Placebo
Oral capsules
Treatment: Drugs: Navocaftor
Oral capsules
Treatment: Drugs: ABBV-119
Oral capsules
Query!
Intervention code [1]
0
0
Treatment: Drugs
Query!
Comparator / control treatment
Query!
Control group
Query!
Outcomes
Primary outcome [1]
0
0
Cohorts 1 and 2: Absolute Change From Baseline in Percent Predicted Forced Expiratory Volume in 1 Second (ppFEV1)
Query!
Assessment method [1]
0
0
Percent predicted forced expiratory volume in 1 second (ppFEV1).
Query!
Timepoint [1]
0
0
Up to 29 days
Query!
Primary outcome [2]
0
0
Cohort 3: Absolute change in Sweat Chloride (SwCl).
Query!
Assessment method [2]
0
0
Sweat chloride (SwCl) concentration is a biomarker of cystic fibrosis transmembrane conductance regulator (CFTR) ion channel function.
Query!
Timepoint [2]
0
0
Up to 29 days
Query!
Secondary outcome [1]
0
0
Cohorts 1 and 2: Absolute Change From Baseline in Sweat Chloride (SwCl)
Query!
Assessment method [1]
0
0
SwCl concentration is a biomarker of cystic fibrosis transmembrane conductance regulator (CFTR) ion channel function.
Query!
Timepoint [1]
0
0
Up to 29 days
Query!
Secondary outcome [2]
0
0
Absolute Change From Baseline in Forced Vital Capacity [FVC]
Query!
Assessment method [2]
0
0
Forced vital capacity (FVC).
Query!
Timepoint [2]
0
0
Up to 29 days
Query!
Secondary outcome [3]
0
0
Absolute Change From Baseline in Forced Expiratory Flow at Mid-Lung Capacity [FEF25-75]
Query!
Assessment method [3]
0
0
Forced expiratory flow between 25% and 75% of exhaled volume (FEF25-75).
Query!
Timepoint [3]
0
0
Up to 29 days
Query!
Secondary outcome [4]
0
0
Relative Changes From Baseline in Percent Predicted Forced Expiratory Volume in 1 Second (ppFEV1)
Query!
Assessment method [4]
0
0
Percent predicted forced expiratory volume in 1 second (ppFEV1).
Query!
Timepoint [4]
0
0
Up to 29 days
Query!
Secondary outcome [5]
0
0
Relative Changes From Baseline in Forced Vital Capacity [FVC]
Query!
Assessment method [5]
0
0
Forced vital capacity (FVC).
Query!
Timepoint [5]
0
0
Up to 29 days
Query!
Secondary outcome [6]
0
0
Relative Changes From Baseline in Forced Expiratory Flow Between 25% and 75% of Exhaled Volume (FEF25-75)
Query!
Assessment method [6]
0
0
Forced expiratory flow between 25% and 75% of exhaled volume (FEF25-75).
Query!
Timepoint [6]
0
0
Up to 29 days
Query!
Secondary outcome [7]
0
0
Absolute Change in CF Questionnaire-Revised (CFQ-R) Respiratory Domain Score From Baseline
Query!
Assessment method [7]
0
0
The CFQ-R is designed for use in participants with a diagnosis of cystic fibrosis and is designed to measure impact on overall health, daily life, perceived well-being, and symptoms. Participants will complete the CFQ-R electronically via a tablet device.
Query!
Timepoint [7]
0
0
Up to 29 days
Query!
Secondary outcome [8]
0
0
Cohort 3: Absolute Changes From Baseline in ppFEV1
Query!
Assessment method [8]
0
0
Percent predicted forced expiratory volume in 1 second (ppFEV1).
Query!
Timepoint [8]
0
0
Up to 29 days
Query!
Eligibility
Key inclusion criteria
- Confirmed clinical diagnosis of cystic fibrosis (CF).
- Arm 1 participants with genotype homozygous for the F508del CF transmembrane
conductance regulator (CFTR) mutation and not receiving
elexacaftor/tezacaftor/ivacaftor (ETI) treatment .
- Arm 2 and 3 participants with genotype heterozygous for the F508del CFTR mutation and
a minimal function and not receiving ETI treatment.
- Arm 4 participants with genotype either homozygous or heterozygous for the F508del
mutation. Participants must be receiving stable (ETI) treatment.
- Percent predicted forced expiratory volume in 1 second (ppFEV1) >= 40% and <=90% of
predicted normal for age, gender and height at screening.
- For arms 1 and 2: sweat chloride (SwCl) >= 60 mmol/L at screening. For participants
who participated in Study M19-530, it is acceptable to use a SwCl value that the
central lab provided in Study M19-530 to establish eligibility.
- Weight >= 35 kg at screening and Day -28 for arm 1 or day 1 for arms 2 to 4.
Query!
Minimum age
18
Years
Query!
Query!
Maximum age
No limit
Query!
Query!
Sex
Both males and females
Query!
Can healthy volunteers participate?
No
Query!
Key exclusion criteria
- Clinically significant laboratory values at screening that would pose undue risk for the
participant or interfere with safety assessments (per the investigator).
Query!
Study design
Purpose of the study
Treatment
Query!
Allocation to intervention
Randomised controlled trial
Query!
Procedure for enrolling a subject and allocating the treatment (allocation concealment procedures)
Query!
Methods used to generate the sequence in which subjects will be randomised (sequence generation)
Query!
Masking / blinding
Blinded (masking used)
Query!
Who is / are masked / blinded?
The people receiving the treatment/s
The people administering the treatment/s
The people analysing the results/data
Query!
Query!
Query!
Query!
Intervention assignment
Parallel
Query!
Other design features
Query!
Phase
Phase 2
Query!
Type of endpoint/s
Query!
Statistical methods / analysis
Query!
Recruitment
Recruitment status
Terminated
Query!
Data analysis
Query!
Reason for early stopping/withdrawal
Query!
Other reasons
Query!
Date of first participant enrolment
Anticipated
Query!
Actual
20/09/2021
Query!
Date of last participant enrolment
Anticipated
Query!
Actual
Query!
Date of last data collection
Anticipated
Query!
Actual
5/06/2023
Query!
Sample size
Target
Query!
Accrual to date
Query!
Final
48
Query!
Recruitment in Australia
Recruitment state(s)
NSW,QLD,SA,VIC,WA
Query!
Recruitment hospital [1]
0
0
Royal Prince Alfred Hospital /ID# 228781 - Camperdown
Query!
Recruitment hospital [2]
0
0
Westmead Hospital /ID# 227281 - Westmead
Query!
Recruitment hospital [3]
0
0
Mater Misericordiae Limited /ID# 227279 - South Brisbane
Query!
Recruitment hospital [4]
0
0
Royal Adelaide Hospital /ID# 228486 - Adelaide
Query!
Recruitment hospital [5]
0
0
Alfred Health /ID# 227283 - Melbourne
Query!
Recruitment hospital [6]
0
0
Royal Children's Hospital /ID# 227280 - Parkville
Query!
Recruitment hospital [7]
0
0
Institute for Respiratory Health /ID# 227624 - Nedlands
Query!
Recruitment postcode(s) [1]
0
0
2050 - Camperdown
Query!
Recruitment postcode(s) [2]
0
0
2145 - Westmead
Query!
Recruitment postcode(s) [3]
0
0
4101 - South Brisbane
Query!
Recruitment postcode(s) [4]
0
0
5000 - Adelaide
Query!
Recruitment postcode(s) [5]
0
0
3004 - Melbourne
Query!
Recruitment postcode(s) [6]
0
0
3052 - Parkville
Query!
Recruitment postcode(s) [7]
0
0
6009 - Nedlands
Query!
Recruitment outside Australia
Country [1]
0
0
United States of America
Query!
State/province [1]
0
0
Alabama
Query!
Country [2]
0
0
United States of America
Query!
State/province [2]
0
0
California
Query!
Country [3]
0
0
United States of America
Query!
State/province [3]
0
0
Florida
Query!
Country [4]
0
0
United States of America
Query!
State/province [4]
0
0
Kansas
Query!
Country [5]
0
0
United States of America
Query!
State/province [5]
0
0
Massachusetts
Query!
Country [6]
0
0
United States of America
Query!
State/province [6]
0
0
Michigan
Query!
Country [7]
0
0
United States of America
Query!
State/province [7]
0
0
Missouri
Query!
Country [8]
0
0
United States of America
Query!
State/province [8]
0
0
New Hampshire
Query!
Country [9]
0
0
United States of America
Query!
State/province [9]
0
0
New York
Query!
Country [10]
0
0
United States of America
Query!
State/province [10]
0
0
Ohio
Query!
Country [11]
0
0
United States of America
Query!
State/province [11]
0
0
Oklahoma
Query!
Country [12]
0
0
United States of America
Query!
State/province [12]
0
0
Pennsylvania
Query!
Country [13]
0
0
United States of America
Query!
State/province [13]
0
0
South Carolina
Query!
Country [14]
0
0
United States of America
Query!
State/province [14]
0
0
Tennessee
Query!
Country [15]
0
0
United States of America
Query!
State/province [15]
0
0
Texas
Query!
Country [16]
0
0
United States of America
Query!
State/province [16]
0
0
Virginia
Query!
Country [17]
0
0
United States of America
Query!
State/province [17]
0
0
Wisconsin
Query!
Country [18]
0
0
Belgium
Query!
State/province [18]
0
0
Antwerpen
Query!
Country [19]
0
0
Belgium
Query!
State/province [19]
0
0
Bruxelles-Capitale
Query!
Country [20]
0
0
Belgium
Query!
State/province [20]
0
0
Oost-Vlaanderen
Query!
Country [21]
0
0
Belgium
Query!
State/province [21]
0
0
Vlaams-Brabant
Query!
Country [22]
0
0
Hungary
Query!
State/province [22]
0
0
Budapest
Query!
Country [23]
0
0
Netherlands
Query!
State/province [23]
0
0
Zuid-Holland
Query!
Country [24]
0
0
Netherlands
Query!
State/province [24]
0
0
Amsterdam
Query!
Country [25]
0
0
Netherlands
Query!
State/province [25]
0
0
Den Haag
Query!
Country [26]
0
0
New Zealand
Query!
State/province [26]
0
0
Auckland
Query!
Country [27]
0
0
New Zealand
Query!
State/province [27]
0
0
Canterbury
Query!
Country [28]
0
0
Slovakia
Query!
State/province [28]
0
0
Banska Bystrica
Query!
Country [29]
0
0
Slovakia
Query!
State/province [29]
0
0
Bratislava
Query!
Country [30]
0
0
United Kingdom
Query!
State/province [30]
0
0
Hampshire
Query!
Country [31]
0
0
United Kingdom
Query!
State/province [31]
0
0
Lancashire
Query!
Country [32]
0
0
United Kingdom
Query!
State/province [32]
0
0
Nottinghamshire
Query!
Country [33]
0
0
United Kingdom
Query!
State/province [33]
0
0
Scotland
Query!
Country [34]
0
0
United Kingdom
Query!
State/province [34]
0
0
Wales
Query!
Country [35]
0
0
United Kingdom
Query!
State/province [35]
0
0
Cambridge
Query!
Country [36]
0
0
United Kingdom
Query!
State/province [36]
0
0
Leeds
Query!
Country [37]
0
0
United Kingdom
Query!
State/province [37]
0
0
London
Query!
Funding & Sponsors
Primary sponsor type
Commercial sector/Industry
Query!
Name
AbbVie
Query!
Address
Query!
Country
Query!
Ethics approval
Ethics application status
Query!
Summary
Brief summary
Cystic Fibrosis (CF) is a rare, life-threatening, genetic disease that affects the lungs and
digestive system, significantly impairing the quality of life, with those affected having a
median age of death at 40. The main objective of this study is to assess how safe and
effective is the combination therapy of galicaftor/navocaftor/ABBV-119 or
Galicaftor/Navocaftor/ABBV-576 in adult participants with CF who are homozygous or
heterozygous for the F508del mutation in each arm.
Galicaftor/Navocaftor/ABBV-119 combination therapy and Galicaftor/Navocaftor/ABBV-576 is
being developed as an investigational drug for the treatment of CF. Study doctors place
participants in 1 of the 4 groups, called treatment arms. Each group receives a different
treatment. Around 90 adult participants with a diagnosis of CF will be enrolled in the study
around approximately 35 sites worldwide.
Participants in arm 1 will receive oral capsules of galicaftor/navocaftor dual combination
for 28 days followed by galicaftor/navocaftor/ABBV-119 triple combination for 28 days.
Participants in arms 2 and 3 will receive the galicaftor/navocaftor/ABBV-119 triple
combination or placebo for 28 days. Participants in arm 4 will receive
galicaftor/navocaftor/ABBV-576 triple combination therapy for 28 days. For all study arms,
ABBV-576, galicaftor, navocaftor, will be given once daily and ABBV-119 twice a day.
There may be higher treatment burden for participants in this trial compared to their
standard of care. Participants will attend regular visits during the study at a hospital or
clinic. The effect of the treatment will be checked by medical assessments, blood tests,
checking for side effects and completing questionnaires.
Query!
Trial website
https://clinicaltrials.gov/ct2/show/NCT04853368
Query!
Trial related presentations / publications
Query!
Public notes
Query!
Contacts
Principal investigator
Name
0
0
ABBVIE INC.
Query!
Address
0
0
AbbVie
Query!
Country
0
0
Query!
Phone
0
0
Query!
Fax
0
0
Query!
Email
0
0
Query!
Contact person for public queries
Name
0
0
Query!
Address
0
0
Query!
Country
0
0
Query!
Phone
0
0
Query!
Fax
0
0
Query!
Email
0
0
Query!
Contact person for scientific queries
Summary Results
For IPD and results data, please see
https://clinicaltrials.gov/ct2/show/NCT04853368
Download to PDF